Hepatoblastoma
Symptoms, Doctors, Treatments, Advances & More

Hepatoblastoma Overview

Save information for later
Sign Up

Learn About Hepatoblastoma

What is the definition of Hepatoblastoma?
Hepatoblastoma is a rare malignant (cancerous) tumor of the live, usually affecting young children. In early stages of the condition, there may be no concerning signs or symptoms. As the tumor gets larger, affected children may experience a painful, abdominal lump; swelling of the abdomen; unexplained weight loss; loss of appetite; and/or nausea and vomiting. The exact underlying cause of Hepatoblastoma is poorly understood. Risk factors for the tumor include prematurity with a very low birth weight, early exposure to hepatitis B infection, biliary atresia, and several different genetic conditions (i.e. Beckwith-Wiedemann syndrome, familial adenomatous polyposis, Aicardi syndrome, Glycogen storage disease, and Simpson-Golabi-Behmel syndrome).
What are the alternative names for Hepatoblastoma?
  • Hepatoblastoma
Who are the top Hepatoblastoma Local Doctors?
Elite in Hepatoblastoma
Dr. Rakesh Sindhi
General Surgery
Elite in Hepatoblastoma
Dr. Rakesh Sindhi
General Surgery

UPMC Children's Hospital Of Pittsburgh, Pediatric Transplant Services

4401 Penn Avenue, 
Pittsburgh, PA 
412-530-6840
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Rakesh Sindhi, MD, FACS, is a pediatric abdominal transplant surgeon, board-certified in surgery by the American Board of Surgery. He is co-director of Pediatric Transplantation, director of Pediatric Transplant Research, and professor of surgery at the University of Pittsburgh School of Medicine. Dr. Sindhi is rated as an Elite provider by MediFind in the treatment of Hepatoblastoma. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Hepatoblastoma, Biliary Atresia, Liver Failure, Liver Transplant, and Small Bowel Resection. Dr. Sindhi is board certified in American Board Of Surgery. Dr. Sindhi is currently accepting new patients.

Elite in Hepatoblastoma
Eiso Hiyama
Elite in Hepatoblastoma
Eiso Hiyama
Hiroshima, JP 

Eiso Hiyama practices practicing medicine in Hiroshima, Japan. Hiyama is rated as an Elite expert by MediFind in the treatment of Hepatoblastoma. They are also highly rated in 5 other conditions, according to our data. Their clinical expertise encompasses Hepatoblastoma, Neuroblastoma, Liver Cancer, Pancreaticoduodenectomy, and Hepatectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Hepatoblastoma
Stefano Cairo
Elite in Hepatoblastoma
Stefano Cairo
Evry, FR 

Stefano Cairo practices practicing medicine in Evry, France. Mr. Cairo is rated as an Elite expert by MediFind in the treatment of Hepatoblastoma. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Hepatoblastoma, Liver Cancer, Breast Cancer, and Triple-Negative Breast Cancer.

View All Doctors
What are the latest Hepatoblastoma Clinical Trials?
A Phase I Study of Vorinostat in Combination With Vincristine, Irinotecan, and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors and CNS Malignancies
A Phase I Study of Vorinostat in Combination With Vincristine, Irinotecan, and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors and CNS Malignancies
Who is this study for: Children, adolescents, and young adults with relapsed or refractory solid tumors and CNS malignancies
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Drug
Study Drug: Vorinostat
Study Phase: Phase 1

Summary: Investigators are testing new experimental drug combinations such as the combination of vorinostat, vincristine, irinotecan, and temozolomide in the hopes of finding a drug that may be effective against tumors that have come back or that have not responded to standard therapy. The goals of this study are: * To find the highest safe dose of vorinostat that can be given together with vincristine, ir...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors
Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors. The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and ...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center